Patent classifications
C07C59/115
[18F]-LABELLED LACTATE DERIVATIVE AS PET RADIOTRACER
A positron emission tomography (PET) radiotracer for imaging lactate uptake, wherein the tracer is a [18F]-labelled lactate derivative. Also, a process for the radiosynthesis of the [18F]-labelled lactate derivative. Further, the use of the [18F]-labelled lactate derivative for imaging lactate uptake in living cells, especially in humans.
[18F]-LABELLED LACTATE DERIVATIVE AS PET RADIOTRACER
A positron emission tomography (PET) radiotracer for imaging lactate uptake, wherein the tracer is a [18F]-labelled lactate derivative. Also, a process for the radiosynthesis of the [18F]-labelled lactate derivative. Further, the use of the [18F]-labelled lactate derivative for imaging lactate uptake in living cells, especially in humans.
Derivatives of sobetirome
Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.
Derivatives of sobetirome
Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.
DERIVATIVES OF SOBETIROME
Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.
DERIVATIVES OF SOBETIROME
Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.
[.SUP.18.F]-labelled lactate derivative as pet radiotracer
A positron emission tomography (PET) radiotracer for imaging lactate uptake, wherein the tracer is a [.sup.18F]-labelled lactate derivative which is [.sup.18F]-3-fluoro-2-hydroxypropionic acid: ##STR00001##
Also, a process for the radiosynthesis of the [.sup.18F]-labelled lactate derivative. Further, the use of the [.sup.18F]-labelled lactate derivative for imaging lactate uptake in living cells, especially in humans.
[.SUP.18.F]-labelled lactate derivative as pet radiotracer
A positron emission tomography (PET) radiotracer for imaging lactate uptake, wherein the tracer is a [.sup.18F]-labelled lactate derivative which is [.sup.18F]-3-fluoro-2-hydroxypropionic acid: ##STR00001##
Also, a process for the radiosynthesis of the [.sup.18F]-labelled lactate derivative. Further, the use of the [.sup.18F]-labelled lactate derivative for imaging lactate uptake in living cells, especially in humans.
RESIST COMPOSITION AND PATTERNING PROCESS
A resist composition comprising a base polymer and a quencher containing a sulfonium salt having an iodized benzene ring offers a high sensitivity, minimal LWR and improved CDU independent of whether it is of positive or negative tone.
RESIST COMPOSITION AND PATTERNING PROCESS
A resist composition comprising a base polymer and a quencher containing a sulfonium salt having an iodized benzene ring offers a high sensitivity, minimal LWR and improved CDU independent of whether it is of positive or negative tone.